Key facts
- This page summarizes Daniel Char's Form 4 filing for ImmunoGen, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 05 Feb 2024, 21:28.
Daniel Char - 01 Feb 2024 Form 4 Insider Report for ImmunoGen, Inc.
- Form type
- 4
- Accepted by SEC
- 05 Feb 2024, 21:28:20 UTC
- Previous filing
- 30 Nov 2022
- Next filing
- 12 Feb 2024
- SEC filing
- View source filing
- Reporting owner signature
- /s/ Renee Lentini, Attorney-in-Fact
Source evidence
Original filing metadata and source links.
5 source fields
Reporting owner
1 detail
Key filing fact
Daniel Char filed Form 4 for ImmunoGen, Inc. on 05 Feb 2024.
Change
- Previous filing in this sequence was filed on 30 Nov 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IMGN
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +22,825
- Change %
- Price
- $0.000000
- Shares after
- 22,825
- Date
- 01 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 22,825
- Exercise price
- $0.000000
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
Footnote F2
The RSUs vest over a three-year period, with 33 1/3% of the RSUs vesting on each of the first three anniversaries of the date of grant, subject to continued service through each vesting date.